Alector, Inc. (ALEC, Financial) experienced a significant stock drop of 5.23% as its shares were recently priced at $5.26. The trading volume reached 242,581 shares, with a turnover rate of 0.25% and a fluctuation of 7.57%.
Financial reports reveal Alector's revenue at $15.34 million, but the company reported a net loss of $42.22 million, leading to an earnings per share (EPS) of -$0.43. The gross profit stood at $13.15 million with a negative price-to-earnings (P/E) ratio of -3.08.
Analyst ratings indicate mixed sentiments with 73% of participating firms giving a 'buy' recommendation, 18% suggesting 'hold,' and 9% advising a 'sell.'
The broader biotechnology industry saw a slight decline of 0.45%. Within this sector, companies such as Nkgen Biotech Inc, Pulmatrix, Inc., and Calidi Biotherapeutics, Inc. showed notable gains. Stocks like Elevai Labs, Inc. and Cyclacel Pharmaceuticals, Inc. recorded significant turnover rates, while companies like Psyence Biomedical Ltd and Pulmatrix, Inc. experienced large fluctuations.
Alector Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegeneration by restoring immune function in the brain. Its product pipeline includes AL001, AL002, AL003, and AL101.
